Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma

Tomoko Aoki\textsuperscript{a} Naoshi Nishida\textsuperscript{a} Kazuomi Ueshima\textsuperscript{a} Masahiro Morita\textsuperscript{a} Hirokazu Chishina\textsuperscript{a} Masahiro Takita\textsuperscript{a} Satoru Hagiwara\textsuperscript{a} Hiroshi Ida\textsuperscript{a} Yasunori Minami\textsuperscript{a} Akira Yamada\textsuperscript{b} Keitaro Sofue\textsuperscript{c} Masakatsu Tsurusaki\textsuperscript{d} Masatoshi Kudo\textsuperscript{a}

\textsuperscript{a}Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; \textsuperscript{b}Department of Radiology, Shinshu University School of Medicine, Nagano, Japan; \textsuperscript{c}Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan; \textsuperscript{d}Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Keywords
Anti-programmed cell death protein 1 · Programmed death-ligand 1 antibody · Hepatocellular carcinoma · Gadolinium-ethoxybenzyl-diethylenetriamine-enhanced magnetic resonance imaging · Wnt/β-catenin · Imaging biomarker

Abstract
Introduction: Immune checkpoint inhibitors (ICIs) are promising agents for the treatment of hepatocellular carcinoma (HCC). However, the establishment of noninvasive measure that could predict the response to ICIs is challenging. This study aimed to evaluate tumor responses to ICIs using the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), which was shown to reflect Wnt/β-catenin activating mutation. Methods: A total of 68 intrahepatic HCC nodules from 18 patients with unresectable HCC and Child-Pugh class A liver function who received anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy were enrolled in this study. All patients had viable intrahepatic lesions evaluable using the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI within the 6 months prior to the treatment. The relative enhancement ratio was calculated, and the time to nodular progression (TTnP) defined as 20% or more increase in each nodule was compared between higher or hypo-enhancement HCC nodules. Then, the progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) were compared between patients with and without HCC nodules with higher enhancement on hepatobiliary phase images. Results: The median PFS was 2.7 (95% confidence interval [CI]: 1.4–4.0) months in patients with HCC nodules with higher enhancement (n = 8) and 5.8 (95% CI: 0.0–18.9) months in patients with hypointense HCC nodules (n = 10) (p = 0.007). The median TTnP of HCC nodules with higher enhancement (n = 23) was 1.97 (95% CI: 1.86–2.07) months and that of hypointense HCC nodules (n = 45) was not reached (p = 0.003). The ORR was 12.5% (1/8) versus...
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, and many patients present with an unresectable disease [1–4]. In this scenario, systemic chemotherapy is required, which includes several molecular targeted agents (MTAs), such as sorafenib [5, 6], lenvatinib [7], regorafenib [8], ramucirumab [9], and cabozantinib [10]. These MTAs were demonstrated to have survival benefit noninferior to sorafenib or over placebo. On the other hand, immune checkpoint inhibitors (ICIs) are a promising therapy for unresectable HCC and have been shown to possess durable antitumor activity [11–14]. Antibodies against the programmed cell death 1 (PD-1) have shown prolonged antitumor responses in patients with advanced HCC and Child-Pugh class A liver function [11, 12]. The Food and Drug Administration approved the anti-PD-1 antibodies such as nivolumab [11] and pembrolizumab [12] as second-line therapies for patients with HCC whose disease progressed on prior sorafenib treatment. However, phase 3 clinical trials failed to show survival benefits of anti-PD-1 antibodies for unresectable HCC in both first- and second-line settings [15, 16]. These results revealed that approximately 30–36% of the patients with unresectable HCC were refractory to ICI monotherapy and had progressive disease (PD) [15, 16], which suggested the presence of potential refractory mechanisms against these agents.

Although all the mechanisms underlying the resistance to ICIs in patients with HCC remain unclear, activating mutations in the Wnt/β-catenin pathway could induce the primary resistance [17, 18]. It has also been reported that HCC with activating mutations in the Wnt/β-catenin signaling block immune cell recruitment and result in poor outcomes following ICI treatment, suggesting a role of the Wnt/β-catenin pathway activation in the establishment of an “immune cold” phenotype in HCC [17–19]. Harding et al. [20] have reported that activating mutations of the Wnt/β-catenin pathway was associated with shorter progression-free survival (PFS) and no tumor response (progressive disease 100%) in patients with HCC who were treated with ICIs. We have also found that combination score involving the status of Wnt/β-catenin activation, degree of tumor infiltrating lymphocyte, and expression of programmed death-ligand 1 (PD-L1) well-stratify the PFS on anti-PD-1 monotherapy [21]. However, to assess the Wnt/β-catenin pathway activation using proteomic and genomic analyses, HCC tissues are required for the analyses of gene expression and alterations of catenin beta-1 (CTNNB1), adenomatous polyposis coli, and AXIN1 and its downstream targets, such as glutamine synthetase. In order to avoid the invasive procedures involved in tissue sampling, an alternative noninvasive measure that reflects the activation of the canonical Wnt/β-catenin pathway is required, which may predict tumor response or resistance to ICI treatment.

Gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) is a gold-standard imaging modality with a high accuracy for diagnosing HCCs [22, 23]. Gd-EOB-DTPA is the liver-specific contrast agent for MRI uptake by hepatocytes through the organic anion transporting polypeptide 1B3 (OATP1B3) [24–27]. OATP1B3 was reported to be one of the downstream targets of the Wnt/β-catenin signaling pathway [28]. The expression of OATP1B3 was demonstrated to be strongly associated with the activation of the Wnt/β-catenin signaling pathway in HCC cases [28, 29]. On the other hand, the immunohistochemical expression of OATP1B3 showed to be strongly correlated with iso-high intensity in hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI [27, 28]. Ueno et al. [28] reported that the activation of the Wnt/β-catenin signaling pathway induced OATP1B3 messenger ribonucleic acid (mRNA) expression in HCC cells and also showed a strong association between OATP1B3 expression and Wnt/β-catenin signaling in human HCC tissues. Collectively, the activation status of the Wnt/β-catenin signaling leads to the iso-high intensity of hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI, which should be an ideal predictive imaging marker for the poor response to ICIs [30].

To date, there are no reports on noninvasive biomarkers for ICIs in HCC, and there is an urgent need to carefully select patients with HCC who can benefit from ICIs.
EOB-MRI as a Noninvasive Responsive Marker of Anti-PD-1/PD-L1 Therapy

In this study, we addressed this important issue and attempted to evaluate the response to anti-PD-1/PD-L1 monotherapy by the analysis of the intensity of HCC nodules on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI.

Materials and Methods

Patients

This single-institution retrospective cohort study enrolled 204 patients with unresectable HCC and Child-Pugh class A liver function who received ICIs from January 1, 2015 to March 31, 2020 at the Kindai University Hospital. The diagnosis of HCC was based on histological and/or radiological findings according to the guidelines proposed by the American Association for the Study of Liver Diseases [31].

The inclusion criteria were as follows: patients with performance status defined by the Eastern Cooperative Oncology Group [32] of 0 or 1, patients with intermediate to advanced stages of HCC treated with anti-PD-1/PD-L1 monotherapy, patients with evaluable intrahepatic lesions on Gd-EOB-DTPA-enhanced MRI examined within 6 months before the start of the PD-1/PD-L1 antibody treatment, those with Child-Pugh class A liver function, and an expected survival time longer than 3 months. The exclusion criteria were as follows: patients with the high risk for esophageal and gastric variceal rupture, patients who refused to participate in this clinical research. The flow diagram for the selection of patients is shown in Figure 1. Eighteen patients with HCC met the criteria and were included in the analysis.

Dose reductions or interruptions were considered if the patients presented severe adverse events (AEs) defined in the Common Terminology Criteria for Adverse Events (CTCAE) v4 (grade ≥3) [33, 34]. The Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) [35] was applied to assess the antitumor response to the target lesion. The tumor response was evaluated by 2 independent imaging experts specialized in HCC. This study was approved by the Institutional Review Board and Medical Ethics Committee of the Kindai University Hospital (IRB approval R02-102), and written informed consent was obtained from all patients.

MRI Protocol

Gd-EOB-DTPA-enhanced MRI was performed using a superconductor magnet system of a 3T scanner (Intera Achieva 3T, Philips Healthcare, Best, The Netherlands) or a 1.5T scanner (1.5T Signa HDxt; GE Healthcare, Milwaukee, WI, USA) with an 8-channel body phased-array coil. Dynamic images using fat-suppressed T1-weighted gradient echo images were obtained before (pre-contrast), 14–30 s (arterial phase), 70 s, and 3 min after intravenous administration of 0.025 mmol per kg of body weight of gadoxetic acid (Primovist; Bayer Schering Pharma, Osaka, Japan) at a rate of 2.0 mL/s, followed by 20 mL of a saline flush. To capture the appropriate timing for arterial phase, a fluoroscopic bolus tracking method was used. In this method, the contrast agent was detected in the proximal abdominal aorta by visual inspection, and automatic detection was performed by placing the region of interest in the abdominal aorta (at the level of the subdiaphragm). The patient was instructed to hold his or her breath 5–10 s after the contrast agent was first detected, after which the arterial phase sequence was acquired. Hepatobiliary phase images were obtained 20 min after the injection of gadoxetic acid. MRI methods are summarized in online suppl. Table 1; for all online suppl. material, see www.karger.com/doi/10.1159/000518048. Two image sets with pre-contrast and hepatobiliary phase images were the focus of evaluation in this study.

Assessment of Tumor Response to ICIs

Among 20 patients who underwent treatment using anti-PD-1/PD-L1 monotherapies, 18 were considered eligible for this study (shown in Fig. 1). The primary endpoint was PFS and the secondary endpoints were overall survival (OS), objective response rate (ORR), time to nodular progression (TTnP, ≥20% increase as compared with baseline) and AEs.
Laboratory tests were performed every 2–4 weeks, and dynamic computed tomography or Gd-EOB-DTPA-enhanced MRI was performed every 4–8 weeks. In case of treatment discontinuation owing to the occurrence of AEs, laboratory tests and diagnostic imaging were repeated every 4–8 weeks until disease progression was observed. The disease control rate (DCR) and ORR were determined based on the best response observed during the treatment and observation periods with anti-PD-1/PD-L1 antibody. For safety assessment, AEs were assessed according to the CTCAE v4 [36]. Among these, 86 hypervascular intrahepatic HCC nodules were depicted using Gd-EOB-DTPA-enhanced MRI by 1 researcher (T.A. with 10 years of experience in hepatology). These nodules were evaluated by 2 independent researchers (K.U. with 25 years of experience in hepatology and M.T. with 25 years of experience in abdominal radiology, especially in liver imaging). Therefore, previously treated nodules, such as transcatheter arterial chemo-embolization and heavy particle beam, were excluded, and the remaining 68 nodules were eligible for analysis. Regions of interest (ROIs) were determined to measure the signal intensities (SI) of the intrahepatic HCC nodules and background liver. Measurements of SI of the intrahepatic HCC nodules were performed at the axial level where the nodule was largest and by placing a round ROI most closely approximating the entire nodule. Additionally, 3 ROIs on areas of background liver parenchyma were placed free of focal hepatic lesions, major branches of the portal or hepatic vein, or imaging artifacts, making sure to place the ROIs at the same positions on the liver parenchyma for each patient. The mean of the 3 ROI measurements was recorded as the SI of the parenchyma in each phase. ROIs of nodules at least 40 (average 150, range 40–1,300) mm² were positioned. The relative enhancement of nodules compared with that of the liver parenchyma was calculated as follows by 2 independent researchers (M.T. and K.S. with 19 years of experience in abdominal radiology, especially in liver imaging), and the average of the 2 values was used for this study. [28, 37]: the relative intensity ratio (RIR) = Snod/SIpar, where Snod is the SI from the nodule and SIpar is that from the liver parenchyma; the relative enhancement ratio (RER) was calculated as RIRHBP/RIRpre, where RIRHBP is RIR in the hepatobiliary phase images and RIRpre is the RIR before the contrast enhancement. Nodules with the activation of Wnt/β-catenin signaling pathway reportedly showed an increase in RER; the optimum RER cutoff point for the determination of Wnt/β-catenin activation was set as 0.90 according to a previous report by Ueno et al. [28]. HCC nodules with higher enhancement on hepatobiliary phase were defined as an RER ≥0.90 and hypointense HCC nodules as an RER <0.90. With this cutoff point, the sensitivity, specificity, and accuracy of prediction of Wnt/β-catenin-activated HCC were 78.9%, 81.7%, and 81.2%, respectively [28].

We evaluated 68 intrahepatic HCC nodules; the Gd-EOB-DTPA-enhanced MRI or dynamic computed tomography examination immediately before ICI treatment was defined as the observation start time, and the maximum diameter of baseline target tumors was measured. The maximum tumor diameter was measured by RECIST v1.1 at each periodic imaging examination, and the nodular progression rate from the baseline was calculated. The time when the tumor progression rate was 20% or more was defined as nodular PD.

Clinical and Laboratory Evaluation

The following test values were collected from medical records within 2 weeks before the initiation of ICI treatments: weight, height, body mass index, platelet counts, prothrombin time-international normalized ratio, serum albumin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, α-fetoprotein (AFP), and des-γ-carboxy prothrombin (DCP). The fibrosis-4 (FIB-4) index was calculated as age (years) × aspartate aminotransferase (IU/L)/(platelet count (10^9/L) × γ-valorine aminotransferase [IU/L]) [38].

Statistical Analyses

Statistical analyses were performed using the IBM Statistical Package for the Social Sciences statistics version 22.0 (IBM, Armonk, NY, USA). A 2-sided p value of <0.05 was considered to indicate statistically significant difference in all analyses. Continuous variables were expressed as median (range), as appropriate. The Kaplan-Meier method and Cox proportional hazards regression models were applied to compare patient survival. When evaluating each nodule, the proportion of nodular PD was compared by RER ratio, and the χ² test or Fisher’s exact test was performed. The TTnP was tested by the Kaplan-Meier curve (log-lank test).

Results

Patient Characteristics

Characteristics of patients at the start of anti-PD-1/PD-L1 monotherapy are summarized in Table 1. The median age of patients was 69 (range, 22–79) years, and 72% (13/18) of the patients were males. In this cohort study, 38.9% (7/18) of the patients were negative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody, and further, 38.9% (7/18) were positive for hepatitis C antibody and 22.2% (4/18) were positive for HBsAg. The median FIB-4 index was 4.01 (range, 0.78–18.02), with 50.0% (9/18) of the patients having a FIB-4 index >4.00. Five of 18 patients (27.8%) were classified as Barcelona clinic liver cancer (BCLC) stage B and 72.2% (13/18) of the patients were BCLC stage C. Vascular invasion and extrahepatic spread were observed in 16.7% (3/18) and 55.6% (10/18) patients, respectively. The baseline median AFP level was 1,957.5 (range, 4.0–52,190) ng/mL; 55.6% (10/18) of patients showed serum AFP level ≥400 ng/mL. The median DCP level was 804 (range, 93–24,227) mAU/mL, with 27.8% (5/18) of the patients showing a serum DCP level ≥400 mAU/mL. Of the 18 patients, 8 received systemic therapy such as sorafenib before ICI treatment.

Eight patients (44%) showed at least 1 HCC nodule with higher enhancement on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI, whereas 10 patients (56%) did not have any higher enhancement HCC nodules on the hepatobiliary phase images. Comparisons of patient characteristics are shown in Table 1. Among pa-
patients with at least 1 higher enhancement HCC nodule, 13% (1/8) had vascular invasion, and 25% (2/8) had extrahepatic spread; BCLC stage C was 38% (3/8), which was significantly lower than those without higher enhancement HCC nodules, where all patients were classified as BCLC stage C (\(p = 0.009\)).

Administration of PD-1/PD-L1 Monotherapy

At the data cutoff date (June 30, 2020), the median duration of follow-up was 26.3 (95% confidence interval [CI]: 13.8–38.8) months (Kaplan-Meier estimate). During the observation period, 12 patients (66.7%) died because of HCC progression. Patients received immunotherapy either as a standard of care or in clinical trials. Of the 18 patients, 14 received anti-PD-1 monotherapy, and 4 patients received anti-PD-L1 monotherapy. The median treatment duration with anti-PD-1/PD-L1 antibody was 3.9 (range, 1.3–40.6) months. Treatment was discontinued in 17 patients due to disease progression (\(n = 14, 77.8\%\)), treatment-related AEs (\(n = 2, 11.1\%\)), or switching to transcatheter arterial chemoembolization (\(n = 1, 5.6\%\)). Only 1 (5.6%) of the 18 patients with a partial response was still undergoing ICI treatment at the data cutoff.

ORR and PFS according to RER in the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI

Among the patients evaluable for tumor response, the ORR and DCR were 22.2% (4/18) and 55.6% (10/18), respectively. The best responses evaluated were as follows: 0% (\(n = 0\)) for complete response (CR), 22.2% (\(n = 4\)) for partial response (PR), 33.3% (\(n = 6\)) for stable disease, and 44.4% (\(n = 8\)) for PD (online suppl. Table 2). The median PFS from the start of anti-PD-1/PD-L1 antibody therapy in all patients was 4.23 (95% CI: 0.42–8.05) months and the median OS was 26.3 (95% CI: 12.8–38.8) months. Among patients with higher enhancement HCC nodules on the hepatobiliary phase images, the ORR and DCR were 12.5% (1/8) and 37.5% (3/8), respectively among patients with hypointense HCC nodules (\(n = 3\)) and 30.0% (3/10) and 70.0% (7/10), respectively among patients with hypointense HCC nodules (\(n = 10\)) (\(p = 0.007\); shown in Fig. 2). A Cox regression analysis adjusted for age ≥65 years, hepatitis virus infection, ALBI grade, albumin-bilirubin grade; FIB-4 index, fibrosis-4 index; AFP, α-fetoprotein; DCP, Des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma.

### Table 1. Patient characteristics at baseline

| Patient characteristic | All patients \((N = 18)\) | Patients with higher enhancement HCC nodules \((n = 8)\) | Patients with hypointense HCC nodules \((n = 10)\) | \(p\) value |
|------------------------|---------------------------|-------------------------------------------------|-------------------------------------------------|------------|
| Age, years, median    | 69 (22, 79)               | 68 (60, 77)                                      | 72 (22, 79)                                      | NS         |
| Gender, male, \(n\) (%) | 13 (72)                  | 6 (75)                                          | 7 (70)                                          | NS         |
| HCV/HBV/NBNC          | 7/4/7                     | 4/1/3                                          | 3/3/4                                          | NS         |
| ECOG PS, 0/1          | 18/0                      | 8/0                                             | 10/0                                           | NS         |
| Maximum tumor size, median, cm | 2.9 (1.0, 10.4) | 2.7 (1.7, 7.0)                                 | 3.4 (1.0, 10.4)                                 | NS         |
| Tumor number, median  | 5 (1, many)               | 7 (2, many)                                     | 3 (1, 6)                                       | 0.077      |
| BCLC stage, 0-A/B/C    | 0/5/13                    | 0/5/3                                          | 0/0/10                                         | 0.009      |
| Vascular invasion, \(n\) (%) | 3 (17)                  | 1 (13)                                         | 2 (20)                                         | NS         |
| Extrahepatic spread, \(n\) (%) | 10 (56)                 | 2 (25)                                         | 8 (80)                                         | 0.077      |
| Child-Pugh score, 5A/6A | 10/8                      | 4/4                                            | 6/4                                            | NS         |
| ALBI score, median    | −2.55 (−3.24, −1.63)      | −2.35 (−3.23, −1.62)                           | −2.76 (−3.18, −1.87)                            | NS         |
| FIB-4 index, median   | 4.01 (0.78, 18.02)        | 4.43 (0.71, 6.38)                               | 2.52 (1.16, 18.0)                               | NS         |
| Serum albumin, median, g/dL | 3.7 (2.9, 4.8) | 3.6 (2.9, 4.3)                                 | 3.8 (3.0, 4.8)                                 | NS         |
| Total bilirubin, median, mg/dL | 0.60 (0.30, 1.70) | 0.70 (0.30, 1.70)                              | 0.60 (0.30, 1.50)                               | NS         |
| Baseline AFP, median, ng/mL | 1,957.5 (4.0, 52,190) | 1,564 (4.0, 19,490)                           | 3,224 (4.0, 52,190)                            | NS         |
| Baseline DCP, median, mAU/mL | 804 (93, 24,227) | 572 (93, 18,340)                               | 869 (144, 24,227)                              | NS         |

Values were expressed as median (range). HCV, hepatitis C virus; HBV, hepatitis B virus; NBNC, HBV and HCV negative; BCLC, Barcelona clinic liver cancer; ALBI grade, albumin-bilirubin grade; FIB-4 index, fibrosis-4 index; AFP, α-fetoprotein; DCP, Des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma.
mL, and DCP level ≥800 mAU/mL showed that the hazard ratio was 7.78 (95% CI: 1.59–38.1, \( p = 0.011 \)) in patients having higher enhancement HCC nodules defined by RER ≥0.90 (Table 2). The median OS from the start of anti-PD-1/PD-L1 checkpoint therapy was 29.0 (95% CI: 12.2–45.8) months in the patients with at least 1 higher enhancement HCC nodules, and 24.5 (95% CI: 13.1–35.9) months in the patients with hypointense HCC nodules (\( p = 0.523 \); online suppl. Fig. 1).

### Table 2: Results of Cox regression analysis (forced entry method)

| Category         | Hazard ratio | 95% CI     | \( p \) value |
|------------------|--------------|------------|---------------|
| HCV infection    | 1.85         | 0.30–11.4  | 0.509         |
| HBV infection    | 2.96         | 0.34–26.1  | 0.329         |
| Age ≥65 years    | 1.30         | 0.31–5.47  | 0.723         |
| ALBI grade       | 2.61         | 0.51–13.4  | 0.250         |
| AFP ≥400         | 1.00         | 0.20–5.04  | 0.997         |
| DCP ≥800         | 1.38         | 0.15–12.9  | 0.779         |
| RER ≥0.90        | 7.78         | 1.59–38.1  | 0.011         |

Of the 18 cases, 4 were censored and 14 had progressive disease. True clinical outcome (dependent variables) were PFS or time to progression (TTP) and cox regression analysis was performed with HCV, HBV, age ≥65, ALBI grade, AFP ≥400, DCP ≥800, and RER ≥0.90 as independent variables. HCV, hepatitis C virus; HBV, hepatitis B virus; AFP, \( \alpha \)-fetoprotein; ALBI, albumin bilirubin; DCP, des-\( \gamma \)-carboxy prothrombin; RER, relative enhancement ratio; CI, confidence interval; PFS, progression-free survival.

### Time to Nodular Progression and PD Rate in Each Nodule

A total of 68 hypervascular HCC nodules in 18 patients without a past treatment history were retrospectively examined for antitumor response against corresponding nodules. The characteristics of these nodules are shown in Table 3 and Figure 3. HCC nodules with higher enhancement on the hepatobiliary phase images were observed in 23 of 68 nodules, and hypointense HCC nodules were observed in 45 of 68 nodules. We used the average RER values measured by 2 independent radiologists. By using the average RER of 2 readers, most of the discrepancies between visual assessment and RER on nodules were finally fixed, but discrepancy was still observed in a few nodules with heterogeneous areas and fat deposits. The median tumor size was 1.5 (range, 0.8–4.0) cm for higher enhancement HCC nodules and 1.7 (range, 0.8–10.4) cm for hypointense HCC nodules. We calculated the contrast-to-noise ratio for the hepatobiliary phase and enhancement ratio, which were used to evaluate the
Table 3. Clinical characteristics of intrahepatic HCC nodules

| Feature                          | Higher enhancement HCC nodules (n = 23) | Hypointense HCC nodules (n = 45) | p value |
|---------------------------------|----------------------------------------|---------------------------------|--------|
| Tumor size, median, cm          | 1.5 (0.8, 4.0)                          | 1.7 (0.8, 10.4)                 | NS     |
| RER,* median                    | 1.04 (0.92, 6.32)                       | 0.72 (0.17, 0.89)               | <0.001 |
| CNR on HBP,** median            | 3.6 (−4.8, 14.4)                       | 11.9 (4.0, 42.4)                | 0.031  |
| Enhancement ratio,*** median    | 0.16 (−0.62, 2.99)                      | 0.012 (−0.51, 1.70)             | 0.039  |
| ADC, median                      | 1.16 (0.61, 1.72)                       | 1.14 (0.61, 2.06)               | NS     |

RER was measured by 2 independent radiologists and the average of the 2 values was used for the study. HCC nodules with higher enhancement on hepatobiliary phase were defined as those showing RER ≥0.90. We express the inspection value in median (range). RER, relative enhancement ratio; RIR, relative intensity ratio; CNR on HBP, contrast-to-noise ratio on hepatobiliary-phase; ADC, apparent diffusion coefficient; HCC, hepatocellular carcinoma; SD, standard deviation; SI, signal intensity; SD background, standard deviation of the background noise; SInod, nodule SI; Spar, liver parenchyma SI. * RER: RIR(HBP)/RIR(pre), where RIR(HBP) is RIR in the hepatobiliary-phase images and RIR(pre) is the precontrast RIR. RIR = SInod/Spar. ** CNR on HBP: CNR = (SInod − Spar)/SD background. *** Enhancement ratio: the enhancement ratio during the hepatobiliary phase was calculated as (SIpost − SIlpre)/SIlpre.
signal value, instead of RER, and we observed a good correlation between these values and RER.

The waterfall plots for each higher enhancement nodule and hypointense nodule classified by RER were shown in online suppl. Figure 2. The proportion of nodular PD, which defined as a tumor size increase above the specified threshold (20% per RECIST v1.1), was 43.5% (10/23) on higher enhancement HCC nodules and 33.3% (15/45) on hypointense HCC nodules. The time to progression of each nodule above the specified threshold (20% per RECIST v1.1), TTnP, was 1.97 (95% CI: 1.86–2.07) months in HCC nodules with higher enhancement. It was not reached in hypointense HCC nodules (p = 0.003). RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; HCC, hepatocellular carcinoma.

**Safety**

Observed AEs of any grade are described in Table 4. AEs were observed in 15 patients (83.3%), with grade 3 or 4 AEs occurring in 6 (33.3%) patients. The most common AE was pruritus (n = 8, 44.4%), which is considered a grade 2 or low-grade AEs. Liver dysfunction was the second most common AE (n = 5, 27.8%), and 1 (5.6%) of them had grade 4 liver injury and required administration of systemic corticosteroids. Upper gastrointestinal bleeding from esophageal varices occurred in 1 (5.6%), nasal bleeding occurred in 1 (5.6%), upper airway bleeding occurred in 1 (5.6%), bacteremia occurred in 2 (11.1%), and fulminant type 1 diabetes, adrenal insufficiency, and hypothyroidism occurred in 1 patient (5.6%). The reasons for treatment discontinuation were gastrointestinal bleeding (n = 1, 5.6%) and severe liver injury (n = 1, 5.6%).

**Discussion**

ICIs have been approved for use in different types of malignancies, including melanoma, lung cancer, colorectal cancer, and HCC [39–42]. Monotherapy with ICIs,
EOB-MRI as a Noninvasive Responsive Marker of Anti-PD-1/PD-L1 Therapy

Specifically those targeting PD-1 or PD-L1, has revolutionized the treatment of unresectable HCC [11, 12] because approximately 15–18% of patients achieve a partial or complete response, many of which show durable responses [15, 16].

Based on clinical trials using ICI monotherapies, a subset of HCC could respond to this type of agent, while others showed early PD. Considering the antitumor mechanism of anti-PD-1/PD-L1 antibody, it is reasonable to speculate that the efficacy of ICIs would be affected by the...
Fig. 6. Different response to anti-PD-1/PD-L1 monotherapy in the same case. We experienced different responses to anti-PD-1/PD-L1 monotherapy when the same case had different RER nodules. 70s male with Child-Pugh score 5, HCV positive (post-SVR) patient. After discontinuing sorafenib and other therapies as the 1st to 3rd line, anti-PD-1 monotherapy was started as the 4th line therapy. SNR of the background liver in T1WI was 35.9, and SNR of background liver in hepatobiliary phase was 69.6. The SNR change ratio was 93.9%, which was sufficient to evaluate that the liver parenchyma was well contrasted. a The average RER of the 2 readers was 0.726, then the nodule of segment 4 decreased from 35 mm to 5 mm in 15 months, resulting in PR. b The average RER of the 2 readers was 1.037, then the nodule of segment 2 increased from 10 mm to 48 mm in 15 months, resulting in PD. RER, relative enhancement ratio; HCV, hepatitis C virus; SVR, sustained virological response; RIR, the relative intensity ratio; PD-L1, programmed death-ligand 1; PR, partial response; PD, progressive disease; HBP, hepatobiliary phase; T1WI, T1-weighted image; SNR, signal-to-noise ratio; PD-1, programmed cell death 1.
tumor immune microenvironment and gene mutation status, such as Wnt/β-catenin mutation. There are several factors associated with the primary resistance to PD-1 and PD-L1 antibody, such as the loss of PD-1/PD-L1 expression by tumor cells or antigen-presenting cells [43, 44] and tumor immunogenicity that is mainly attributed to the tumor mutational burden, where microsatellite instability is one of the surrogate markers for predicting the efficiency of ICIs. It has been reported that approximately 11–37% of HCC have Wnt/β-catenin mutation [45]. Activation of the canonical Wnt/β-catenin signaling pathway in HCC decreases in chemokine (c-c motif) ligand 5 (CCL5) production, so the infiltration of CD8+ T cells into the tumor tissues by reducing the recruitment of CD103+ dendritic cells [46, 47], leading to the establishment of an “immune cold tumor” with the absence of antitumor cytotoxic T cell, leading to primary resistance to ICIs as one of the characteristics [18, 20, 47]. Other mechanisms of acquired resistance to PD-1 and PD-L1 antibodies include mutations in β-2 microglobulin that impair antigen presentation [48–50] and alterations in the Janus kinases, signal transducers, and activators of the transcription pathway that affect interferon-γ signaling [51].

Kan et al. [52] described the complete genome sequencing of 88 HCC, and they found the Wnt/β-catenin gene (15.9%) and TP53 (35.2%) to be the most commonly mutated genes, which were also considered as the 2 main oncogenic drivers for hepatocarcinogenesis. Then, it has been reported that TP53 was rarely positive in the Wnt/β-catenin signaling-related marker-positive HCC [53]. Harding et al. [20] have reported that the activating mutations of CTNNB1 or AXIN1 was associated with progressive disease in 100%, and showed a short median PFS in patients with HCC treated with ICIs. Based on the hypothesis that the activation status of the Wnt/β-catenin signaling results in the enhancement of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI [27–30], this study was conducted to predict the antitumor effect of ICIs for patients with unresectable HCC using the signal intensity of intrahepatic HCC nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI.

The frequency of higher enhancement HCC is about 10%, which is smaller than that of Wnt/β-catenin mutation in HCC. One reason is that population in which the mutation was evaluated may be different. HCC with Wnt/β-catenin mutation is originally with a good prognosis, and Wnt/β-catenin mutation has been reported to be 30% in only resectable cases. Its frequency in advanced stage HCC has not been clarified. Another reason is that suppressors of Wnt receptor are affected by methylation and therefore do not always match the reported frequency of gene mutations. It is necessary to compare it with the tumor biopsy, but in this study the target biopsy has not been sufficiently done, therefor further studies are needed to clarity on this point in the future.

The median PFS was significantly shorter in patients with higher enhancement HCC nodules on the hepatobiliary phase images than in those with hypointense HCC nodules (2.7 vs. 5.8 months, \( p = 0.007 \)). Comparing tumor factors, BCLC stage C was significantly more frequent and baseline AFP level and DCP level also tended to be higher in patients without any higher enhancement HCC nodules than in those with higher enhancement HCC nodules which is consistent with the observation by Kitao et al. [27, 53]. It has been reported that HCC with higher enhancement on hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI was related to the good prognosis because of hepatocyte nuclear factor 4 alpha (HNF4α), which may work as a tumor suppressor gene and inhibit the progression of HCC [54]. After the BCLC stage and tumor marker level were adjusted for the analyses, the difference in PFS might be more prominent between the 2 groups.

We also detect significant difference in the analyses of 68 HCC nodules classified based on RER: TTnP is sig-

| AE | All patients (n = 18), n (%) | any grade | grade 3/4 |
|----|-----------------------------|-----------|-----------|
| Pruritus | 8 (44) | 0 (0) | |
| Proteinuria | 1 (6) | 0 (0) | |
| Diarrhea | 1 (6) | 0 (0) | |
| Decreased appetite | 0 (0) | 0 (0) | |
| Fatigue | 0 (0) | 0 (0) | |
| Liver injury or failure | 5 (28) | 1 (6) | |
| Encephalopathy | 0 (0) | 0 (0) | |
| Jaundice | 1 (6) | 1 (6) | |
| Hypoalbuminemia | 0 (0) | 0 (0) | |
| Ascites | 2 (11) | 0 (0) | |
| Peripheral edema | 1 (6) | 0 (0) | |
| Bleeding or hemorrhage | 3 (17) | 1 (6) | |
| Hypothyroidism | 1 (6) | 0 (0) | |
| Arthritis | 1 (6) | 0 (0) | |
| Hyperglycemia | 1 (6) | 1 (6) | |
| Adrenal insufficiency | 1 (6) | 1 (6) | |
| Infection | 2 (11) | 2 (11) | |

PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; AE, adverse event.
nificantly shorter in HCC nodules with higher enhancement on the hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI than that in hypointense HCC nodules (1.97 months vs. not reached, \( p = 0.003 \)). These results strongly support the notion that Wnt/\( \beta \)-catenin activating mutations can be visualized on hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI and HCC nodules with higher enhancement on hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI could be an imaging biomarker to predict poor response to anti-PD-1/PD-L1 monotherapy [30]. However, although we find the association between Gd-EOB-DTPA-uptake and disease control on anti-PD-1/PD-L1 monotherapy, some nodules show discrepancy between tumor response to ICI and intensity on hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI. It is reported that transcription factor HNF4\( \alpha \), which plays a role in maintaining the function of mature hepatocyte, can also induce the expression of OATP1B3, and a decrease in HNF4\( \alpha \) during the de-differentiation of HCC may lead to the downregulation of OATP1B3, regardless of mutational status of Wnt/\( \beta \)-catenin pathway, which results in the loss of Gd-EOB-DTPA uptake [54]. From this point of view, it is conceivable that some HCC nodules may show discordance between Gd-EOB-DTPA uptake and Wnt/\( \beta \)-catenin status. Further analyses should be required to understand the molecular background of the HCCs showing discordance between Gd-EOB-DTPA uptake and tumor response to ICI.

On the other hand, ICI-refractory HCCs often carry Wnt/\( \beta \)-catenin mutations; it has been reported that the Wnt/\( \beta \)-catenin activating mutations are highly correlated with fibroblast growth factor receptor 4 (FGFR4) [55]. In addition, it was shown that ORR and PFS by lenvatinib treatment were extremely favorable in FGFR4 expressed HCCs [55]. In this context, lenvatinib, which has a strong FGFR4 inhibitory activity, is likely to be very effective as a post-anti-PD-1/PD-L1 therapy for ICI refractory patients with HCC [56].

In this study, there is no significant difference in median OS (online suppl. Fig. 1). It has been reported that HCC with higher enhancement is originally low-grade malignancy and has a good prognosis [29, 54]. In addition, even if the effect on anti-PD-1/PD-L1 monotherapy is poor, the prognosis is extended by the natural course along with effects of post-treatment. Then, it may be difficult to make a significant difference in the OS.

Despite the promising results on evaluating RER using Gd-EOB-DTPA-enhanced MRI for ICI treatment, our study has several limitations. First, this study was retrospective in nature and had a small sample size with imbalanced tumor factors. Second, there was no pathological proof, such as immunostaining of glutamine synthetase and \( \beta \)-catenin, or sequencing analysis of CTNNB1, adenomatous polyposis coli, and AXIN1. However, considering the establishment of noninvasive image-based biomarkers to predict the response to anti-PD-1/PD-L1 antibody, the data presented here should be quite informative for the selection of patients who are expected to be non-responders to anti-PD-1/PD-L1 antibody in real-world clinical practice.

**Conclusion**

For patients with unresectable HCC and Child-Pugh class A liver function, RERs on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI are noninvasive useful predictors of poor response to anti-PD-1/PD-L1 monotherapy. Patients with higher enhancement intrahepatic HCC nodules, which may reflect the activation of the Wnt/\( \beta \)-catenin signaling pathway, could be good predictors of poor response to ICI treatments. Future large-scale prospective studies are warranted to confirm our novel observation described in this report.

**Acknowledgement**

We would like to thank Editage (www.editage.com) for English language editing.

**Statement of Ethics**

IRB approval R02-102 (approved in 2020). This study was approved by the Institutional Review Board and Medical Ethics Committee of the Kindai University Hospital (IRB approval R02-102), and the written informed consent was obtained from all the patients.

**Conflict of Interest Statement**

T.A.: no relevant conflicts of interest to disclose. N.N. is an Editorial Board member of LIVER CANCER. K.U. has received Honoraria from Bayer AG, Eisai Co. Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., AbbVie GK, and Kowa Co., Ltd. He has received consulting or advisory fees from Eisai Co. Ltd., Eli Lilly and Company, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Inc. M.M.: no relevant conflicts of interest to disclose. H.C.: no relevant conflicts of interest to disclose.
to disclose. M.T.: no relevant conflicts of interest to disclose. S.H.: no relevant conflicts of interest to disclose. H.I.: no relevant conflicts of interest to disclose. Y.M.: no relevant conflicts of interest to disclose. A.Y.: no relevant conflicts of interest to disclose. K.S.: no relevant conflicts of interest to disclose. M.K.: no relevant conflicts of interest to disclose. M.K. has received grants from Taiho Pharmaceuticals, Chugai Pharmaceuticals, Otsuka, Takeda, Sumitomo Dainippon-Sumitomo, Daiichi Sankyo, AbbVie, Astellas Pharma, and Bristol-Myers Squibb. He has also received grants and personal lecture fees from Merck Sharp and Dohme (MSD), Eisai, and Bayer, and is an adviser for MSD, Eisai, Bayer, Bristol-Myers Squibb, Eli Lilly, Chugai, AstraZeneca, and ONO Pharmaceuticals. He is an editor-in-chief of LIVER CANCER.

**Author Contributions**

Conceptualization: M.K. and K.U.; methodology: M.K.; software: T.A.; validation: T.A.; formal analysis: T.A.; investigation: T.A. and M.T.; data curation, A.Y., K.U., M.M., H.C., M.T., S.H., H.I., and Y.M.; writing – original draft preparation: T.A. and N.N.; writing – review and editing: N.N. and M.K.; visualization: K.S. and M.T.; supervision: M.K.; and project administration: N.N. and M.K.

**Data Availability Statement**

All data generated or analysed during this study are included in this article and its online suppl. files. Further inquiries can be directed to the corresponding author.

**Funding Sources**

This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI: 16K382, N. Nishida, and 18K07922, M. Kudo) and a grant from Smoking Research Foundation (N. Nishida).

**References**

1 Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014 Apr;109(4):542–53.

2 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.

3 European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236.

4 Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the Global Burden of Disease Study 2017. Liver Cancer. 2020 Sep;9(5):563–82.

5 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–90.

6 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34.

7 Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163–73.

8 Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56–66.

9 Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282–96.

10 Abou-Alfa GK, Meyer T, Cheng A-L, El-Houeiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54–63.

11 El-Houeiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492–502.

12 Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940–52.

13 Kudo M. Immuno-oncology therapy for hepatocellular carcinoma: current status and ongoing trials. Liver Cancer. 2019;8(4):221–38.

14 Finn RS, Qin S, Ikeda M, Galle PR, Dureucx M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–905.

15 Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. LBA38_PR: CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). ESMO2019. Ann Oncol. 2019;30(Suppl 5):v874–5.

16 Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouatour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020 Jan 20;38(3):193–202.

17 Sie D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017 Sep;153(3):812–26.

18 Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019 Apr 1;25(7):2021–3.

19 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018 Oct;15(10):599–616.

20 Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019 Apr 1;25(7):2116–26.

21 Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver Cancer. Forthcoming 2021.
Oken MM, Creech RH, Tormey DC, Horton JF, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Group. 1982;34(4):369–86.

Finn RS, Abecassis MM, et al. Diagnosis, staging and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Liver Cancer 2019;8(6):649–55.

Aoki T, Byhardt R, Stetj S, Gwee C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0, an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13–47.

Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemotherapeutic-induced oral mucositis for locally advanced nasopharyngeal cancer. Oral Oncol. 2012 Jun;48(6):554–9.

Therasse P, Arbuck S, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 29;92(3):205–16.

Development. NCIP. Cancer therapy evaluation program. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 2017 Mar 21.

Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multi-step hepatocarcinogenesis: correlation with molecular transporters and histopathologic features. Radiology. 2010 Sep;256(3):817–26.

Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoteric acid-enhanced MR Imaging: correlation with molecular transporters and histopathologic features. Radiology. 2010 Dec;265(3):785–9.

Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoteric acid in hepatocellular carcinoma. J Hepatol. 2014 Nov;61(5):1080–7.

Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Sanada J, et al. Hepatocellular carcinoma with betacatenin mutation: imaging and pathologic characteristics. Radiology. 2015 Jun;275(3):708–17.

Kudo M. Gd-EOB-DTPA-MSRI could predict WNT/β-catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinoma. Liver Cancer. 2020 Sep;9(3):479–90.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guide- line by the American Association for the Study of Liver Diseases. Hepatology. 2018 Aug;68(2):723–50.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–55.